Two Chemotherapy Regimens Plus or Minus Bevacizumab
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Compare the effect of capecitabine (cape) + temozolomide (temo) and of 5FU + streptozotocin
(strepto) given with a new schedule (LV5FU2 + strepto), two of the most used chemotherapy
regimens in the treatment of well differentiated pancreatic neuroendocrine tumors alone or in
combination with bevacizumab (beva) on progression-free survival (PFS) and compare the
chemotherapy regimens alone or with beva (two by two design) on the same criteria.